Thermo Fisher Scientific Inc

TMO: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
<&wLOCK|V^<LOCK|!J&S$?&?

China Remains a Drag on Thermo Fisher's Performance but Environment Should Improve in 2025

Business Strategy and Outlook

Thermo Fisher is weathering the pullback in global biopharmaceutical spending and China softness better than most of its peers. Being the premier life science supplier and having an unmatched portfolio of products, resources, and manufacturing capabilities have allowed the firm to retain and grow its wallet share among its customers across all channels. We expect the current budget-constrained environment to slowly ease in the upcoming year. Thermo Fisher remains in a great position to leverage its share gains in the biopharma channel and capitalize on strong long-term demand.

Sponsor Center